Company intelligence / Profile preview

Anviron

Not specified*, California, United Statesanviron.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

Anviron’s lead candidate, ANV221, has demonstrated in vivo efficacy by reducing tumor size and suppressing metastases in pancreatic ductal adenocarcinoma models, outperforming standard-of-care drugs. It also shows promise in halting tumor growth and potentially reversing drug resistance in triple-negative and HER2+ breast cancers. The company has received Orphan Drug Designation from the FDA for ANV221 targeting pancreatic cancers and is advancing toward clinical trials

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

ANV221

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

University of Tennessee Research Foundation (UTRF)University of Tennessee Health Science Center (UTHSC)

Beyond the preview

Go deeper on Anviron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anviron.

Explore the full profile